heart rhythm News
-
The feasibility of using vMap in patients after COVID-19 Infection presented at THRS 2021.
COVID-19 is associated with myocardial inflammation which may cause or exacerbate arrhythmias. A study led by Dr. David Krummen was presented at the Taiwan Heart Rhythm Society - Cutting-Edge Care for Heart Rhythm on April 17-18, 2021. The study reports that use of vMap™ computational 12-lead ECG analysis was able to provide arrhythmia insights beyond those available from a standard ...
-
Thermedical Announces SERF VT Study Presented as Part of HRS 2020 Science Late-Breaking Clinical Trial Sessions May 2020
WALTHAM, Mass., May 8, 2020 - Thermedicak a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate® catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today. Called the Saline Enhanced Radiofrequency ...
-
Vektor’s vMap Technology Used Alongside SAbR Planning Software (Varian, Palo Alto, CA) for Non-Invasive Mapping and Radio-ablation of Refractory Ventricular Tachycardia
Life-threatening heart rhythm disorders such as ventricular tachycardia may be eliminated using cutting-edge, non-invasive technology as an alternative to standard invasive catheter ablation procedures, in some cases. In an abstract and associated poster published at the American College of Physicians’ Southern Regional Conference, researchers report successful use of vMap™ ...
-
vMap`s Role in Optimizing Non-Invasive Radio-Ablation Therapy presented at ACC.21 and THRS 2021.
A dual-center study reported that vMap™, as part of a new, non-invasive workflow - with Varian’s CRA system - improved efficiency and precision for radio-ablation therapy in these study subjects. The study showed that the radio-ablation administered as a part of the enhanced workflow also significantly reduced ICD shocks for patients receiving the therapy. Presented by its lead ...
-
Impulse Dynamics Receives FDA Approval to Modify Labeling for Optimizer Smart Medical Devices
Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the U.S. Food and Drug Administration approved a modification of labeling for the Optimizer Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement. Since patients are no longer ...
-
IFEMA MADRID will held Heart Failure Congress in 2022
This announcement comes a few months after the ESC selected the Institution as host venue for its global congress for 2025, confirming the attractiveness of IFEMA MADRID and Madrid as a host city for large high-level medical congresses. The HFA comprises more than 10,000 members, and past Heart Failure congresses have hosted 5,500 to 6,000 delegates at their in-person editions. The ...
-
IFEMA will host the ESC Congress in 2025
In 2025, IFEMA will host the annual congress of the European Society of Cardiology, ESC Congress 2025, the largest congress in the world in this speciality, the holding of which will give Madrid a strong boost, confirming the city as a preferred international destination for business tourism. This has been confirmed by the European Society of Cardiology, which annually celebrates its congress, ...
-
Novel String-Shaped Implantable Defibrillator Proves Effective - In Treating Patients with Irregular Heartbeats
CHICAGO, May 12, 2017 - A new study examines the effectiveness of the Implantable Subcutaneous String Defibrillator (ISSD™), a flexible, string-shaped and first-ever rechargeable implantable cardioverter-defibrillator (ICD). This is the first-in-man study to report on the feasibility of the innovative device and was presented today at Heart Rhythm 2017, the Heart Rhythm Society's 38th ...
By NewPace Ltd.
-
Thermedical Scores Fda Breakthrough Designation For Ablation System To Treat Ventricular Tachycardia
Waltham, Mass.-based Thermedical Inc. has received a breakthrough device designation from the U.S. FDA for its saline enhanced radiofrequency (SERF) ablation system and Durablate catheter in the treatment of ventricular tachycardia (VT). The system uses a new means of biological heat to precisely deliver ablation therapy to the heart.VT is a leading cause of sudden cardiac death worldwide – ...
-
Thermedical Announces FDA Breakthrough Device Designation
WALTHAM. Mass.. May 19,2020 - Thermedicak a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT): today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate® catheter. The FDA Breakthrough Devices Program is intended to help ...
-
Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. This PFA system – comprising a sheath, generator and catheters – is intended to ablate ...
-
EBR Systems’ WiSE CRT System Demonstrates Technical Feasibility of Leadless Left Bundle Branch Area Pacing for Cardiac Resynchronization
Published last month in the European Heart Journal, the case report details the successful deployment of the WiSE Electrode implanted in the LV septum of an 82-year-old male with tachyarrhythmia-induced cardiomyopathy. The patient exhibited improved electrical resynchronization on ECG and reported significant symptomatic improvement at six-month follow-up. This is the first reported case of ...
-
Kardium receives CE mark for Globe® Mapping and Ablation System
VANCOUVER, British Columbia – Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System – the most complete solution for the treatment of atrial fibrillation (AF). AF is the world’s most common heart rhythm disorder, affecting more than 37 million people. This approval allows Kardium to begin commercial sales of the Globe System in Europe. “This ...
By Kardium Inc.
-
FARAPULSE’s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation
FARAPULSE Inc. today announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes ...
-
$30 Million Series B Financing and Expansion of Scientific Advisory Board
Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor. Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the ...
-
Kardium’s Globe® System Begins Clinical Trial at St. Paul’s Hospital
VANCOUVER, British Columbia –?Kardium?Inc.?announces a successful first-in-BC investigational* clinical procedure using the Globe® Mapping and Ablation System. Dr. Marc Deyell of St. Paul’s Hospital leads the study using the Globe System to navigate inside the heart and diagnose where the rhythm disturbances occur. Once identified, the same device can then deliver immediate ...
By Kardium Inc.
-
Professor Gust H. Bardy, M.D. of Bardy Diagnostics Partners with Arrhythmia Alliance to Increase Patient Awareness of Heart Arrhythmias and Early Detection
(Seattle, WA – November 17, 2020) – Chief Medical Officer of Bardy Diagnostics and Clinical Professor of Medicine University of Washington Professor Gust H. Bardy sat down with Trudie Lobban, MBE, Founder and CEO of Arrhythmia Alliance, a non-profit organization dedicated to improving the diagnosis, treatment, and quality of life for all those affected by arrhythmias, to discuss the ...
-
Kardium Marks First Commercial Procedures of Globe® Mapping and Ablation System
VANCOUVER, British Columbia – Kardium Inc. announced the first commercial procedures with the Globe Mapping and Ablation System. The Globe System is the most complete solution for the treatment of atrial fibrillation (AF) – the world’s most common heart rhythm disorder, affecting more than 37 million people. The first patients were treated in Europe. During the last few weeks, ...
By Kardium Inc.
-
Kardium® announces new financing to commercialize the Globe® System for the treatment of atrial fibrillation
VANCOUVER, B.C. – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, announced today that it has raised an undisclosed amount in a new financing round. The financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders. Kardium was ...
By Kardium Inc.
-
First-in-Human Trial of Pulsed Field Ablation with Kardium’s Globe® PF System
VANCOUVER, British Columbia – Kardium Inc. announces the completion of successful first-in-human (FIH) procedures with the Globe Pulsed Field System. Dr. Vivek Reddy of Mount Sinai Hospital in New York, USA and Prof. Petr Neužil of Na Homolce Hospital in Prague, Czech Republic, performed the procedures in Prague last week. Dr. Jacob Koruth of Mount Sinai Hospital joined Dr. Reddy and Prof. ...
By Kardium Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you